Reactor Technology's Influence On CDMO Selection

In Q2, 2020, ISR asked 76 biopharma respondents that outsource commercialized products how much influence the contract manufacturer’s reactor technology has on their choice of CDMO. The data show that reactor technology factors into the decision for almost all outsourcers of commercial biologics (95%). Two-thirds of respondents said reactor technology has a moderate or a lot of influence over the decision. To learn more about commercial bioprocessing outsourcer’s preferences and practices, follow the link to ISR’s Commercial Bioprocessing Market Outlook report.